Selskabets formål er enhver aktivitet i forbindelse med salgsfremmende virksomhed og distribution samt produk- tion og forskning og enhver anden beslægtet aktivitet inden for animalsk sundhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 634.4 mio. | 40.4 mio. | 404.6 mio. | 113.6 mio. | 93000 | |
CVR: 13526990
Secondary names: BOEHRINGER INGELHEIM ANIMAL HEALTH NORDICS A/S, BOEHRINGER INGELHEIM AGROVET A/S, BOEHRINGER INGELHEIM VETMEDICA A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Boehringer Ingelheim Animal Health Denmark A/S demonstrates a solid financial health with a notable increase in revenue and profit in 2024, reaching 634.4 million DKK and 40.4 million DKK respectively, up from 585.3 million DKK and 14.5 million DKK in 2023. The company has shown a fluctuating revenue trend over the past few years, with a peak in 2020 at 622.6 million DKK, but overall, it has managed to stabilize and improve its profitability significantly in the latest year. With equity rising to 113.6 million DKK, the company appears to be strengthening its financial position, although the profit margins indicate some volatility. Positioned within the pharmaceutical and healthcare industry, it remains a key player in the animal health sector, leveraging its growing financial metrics to enhance its market presence.
AI-generated summary
Companies in the same industry and area
companydata.dk